Study of Ataluren (PTC124) in Cystic Fibrosis

Stopped early · Phase 3

Conditions studied: Cystic Fibrosis

In brief

The primary objective of this study is to determine the long-term safety and tolerability of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) who completed participation in the double-blind study PTC124-GD-009-CF (NCT00803205), as assessed by adverse events and laboratory abnormalities. The secondary objective of this study includes the assessment of the efficacy of ataluren, as measured by forced expiratory volume in 1 second (FEV1) and pulmonary exacerbation rate, and other safety parameters (for example, 12-lead electrocardiogram \[ECG\] measurements, vital signs).

Key facts

Study ID
NCT02107859
Run by
PTC Therapeutics
People needed
61
Starts
2014-05-23
Expected to finish
2017-06-05
Last updated by the study team
2020-03-25

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.